Sunshine Biopharma closes ~$10M underwritten public offering of units with warrants

Sunshine Biopharma Inc.

71,428,571 Units priced at $0.14/Common Unit and $0.139/Pre-Funded Unit; gross proceeds ~$10.0M.
Each Unit includes common stock (or pre-funded warrant) plus 0.1 Series A ($2.10 strike) and 0.2 Series B ($2.38 strike) warrants.
Underwriter Aegis Capital Corp. partially exercised over-allotment for 2,491,071 Series A and B warrants.
Net proceeds earmarked for general corporate purposes and working capital.
Offering closed on February 15, 2024; warrants expire in 30 months (Series A) and 60 months (Series B).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sunshine Biopharma Inc. entered into Underwriting Agreement with Aegis Capital Corp. valued at approximately $10.0 million (effective 2024-02-13).

Action: entry
Agreement: underwriting
Counterparty: Aegis Capital Corp.
Value: approximately $10.0 million
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, Sunshine Biopharma, Inc., (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (the “Underwriter”), in connection with a firm commitment underwritten public offering (the “Offering”)

View on SEC.gov

Browse all material agreements →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.